Jun. 24, 2020—The Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at Vanderbilt University Medical Center (VUMC), has been named Administrative Coordinating Center (ACC) of a national effort to streamline the research response to life-threatening lung and heart problems caused by COVID-19.
Jun. 24, 2020—The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) held its third annual symposium last week as a virtual, on-line event to preserve social distancing during COVID-19.
Jun. 21, 2020—The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.
Jun. 17, 2020—Throughout June Vanderbilt University Medical Center is welcoming 330 new residents and fellows, and onboarding the physicians-in-training looks a bit different this year.
Jun. 17, 2020—Early data assessing the primary language of those who received COVID-19 tests at Vanderbilt University Medical Center, and tested positive, illustrates the disproportionate impact the pandemic is having on racial or ethnic communities.
Jun. 16, 2020—The number of hospitalized COVID-19 patients reached its highest level to date on June 15, when more than 400 patients were hospitalized across Tennessee, according to a report from researchers at Vanderbilt.
TERAVOLT registry tracks outcomes of treatments among people with thoracic cancers sickened by COVID-19
Jun. 12, 2020—New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
Jun. 9, 2020—REDCap, the research data management tool created and powered by Vanderbilt University Medical Center, is serving extra duty as research teams and public health authorities around the world grapple with the COVID-19 pandemic.
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
Jun. 4, 2020—As of early May, an average of 8,000 VUMC employees were working remotely each day, equaling more than 25% of VUMC’s total workforce.